Simrat Randhawa

Insider activity · 24 months0 buys3 salesCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 3 salesOct 26 · 0 buys · 0 sales

Total declarations

Company

▲ Purchases (2 ops.)

€50k

▼ Sales (8 ops.)

€10.9M

Latest filing published 03 Sept 2026 for Dianthus Therapeutics, Inc. /DE/, €115k.

Filing timeline

BuySale

Simrat Randhawa

Insider track record

Disclosed buys

Disclosed sells

Not enough buy signals with a settled T+90 horizon to measure a track record yet.

Signal history

Simrat Randhawa: trading record in brief

Simrat Randhawa appears in our data through filings on Dianthus Therapeutics, Inc. /DE/ shares, published by SEC (Form 4). The record holds 22 filings, for trades running from 21 September 2023 to 1 September 2026.

Both buying and selling appear: 2 purchases worth €50k, against 8 sales worth €10.9M. Netting one side against the other leaves €10.8M of net selling. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Besides market trades, the filings include 12 option exercises. In 2026 alone, the filings show no purchases and 4 sales.

The newest entry dates from 3 September 2026: an option exercise of €115k, in Dianthus Therapeutics, Inc. /DE/. The latest purchase dates back some time: it was published 1,127 days ago, on 25 September 2023. The median gap between a trade and its publication by SEC (Form 4) is 1 day. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.